Why the study?
Are there survival differences among clinical subgroups of patients with pulmonary arterial hypertension associated with congenital heart disease?
Are there survival differences among clinical subgroups of patients with pulmonary arterial hypertension associated with congenital heart disease?
Survival in PAH-CHD varies significantly by clinical subgroup, with CD and SD having the worst prognosis, which should inform treatment strategies.
May guide risk stratification in PAH-CHD; hypothesis-generating for subgroup-specific therapies pending prospective validation.
Relevant clinical, functional, haemodynamic, and survival differences were observed among subgroups. In particular, patients with CD and SD had the worst survival. These findings should be considered when planning medical or interventional treatment strategies in PAH-CHD patients.
No takes yet. Share an insight, caveat, or question.
Manes et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: